GENTAMYCIN SULFATE

The contract specifies the procurement of 4 packages, each containing twelve 15-gram tubes of OTOMAX ointment, a veterinary pharmaceutical product combining gentamicin sulfate, betamethasone valerate, and clotrimazole, used to treat acute and chronic otitis in canines. Each tube delivers 3 mg of gentamicin base, 1 mg of betamethasone valerate, and 10 mg of clotrimazole, and the item is regulated by the FDA. The unit of issue is a package of 12 tubes, and the shipment must comply with MIL-STD-2073-1E packaging standards and the Medical Marking Standard No. 1, superseding MIL-STD-129 for medical acquisitions. The product has a strict 24-month non-extendable shelf life as a Type I (Code M) item and must be stored between 2°C and 25°C (36°F–77°F). Delivery is required FOB destination to APO AE 09227-0000 within 89 days after award, with inspection and acceptance occurring at the destination. The NSN for this item is 6509015304283, and it is subject to DLA’s Packaging Requirements for Procurement and technical quality standards referenced in the DLA Master List. Hazard communication standards under 29 CFR 1910.1200 apply, and labeling must adhere to FDA and DLA medical marking guidelines. The solicitation, identified as SPE2DP-26-T-3429, was issued on May 17, 2026, with proposals due by May 26, 2026, through the DIBBS portal. The contract includes mandatory flowdown of FAR and DFARS clauses concerning contract type, small business representation, equal opportunity, trafficking in persons, employment eligibility, sustainable products, hazardous material identification, safeguarding covered defense information, and compliance with NIST SP 800-171 requirements. Offerors must provide their Unique Entity ID and CAGE code if they supply covered defense telecommunications equipment or services, and must comply with WAWF for invoice submission. No unit pricing is disclosed in the solicitation, and the contract type remains undefined pending contracting officer designation.